Insulet Co. (NASDAQ:PODD) EVP Aiman Abdel-Malek sold 602 shares of the business’s stock in a transaction that occurred on Friday, September 14th. The shares were sold at an average price of $107.99, for a total value of $65,009.98. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Aiman Abdel-Malek also recently made the following trade(s):

  • On Tuesday, August 14th, Aiman Abdel-Malek sold 602 shares of Insulet stock. The shares were sold at an average price of $86.60, for a total value of $52,133.20.

NASDAQ:PODD opened at $104.61 on Wednesday. Insulet Co. has a 1 year low of $54.55 and a 1 year high of $108.90. The firm has a market capitalization of $6.30 billion, a PE ratio of -227.41 and a beta of 1.57. The company has a quick ratio of 5.01, a current ratio of 5.54 and a debt-to-equity ratio of 3.22.

Insulet (NASDAQ:PODD) last released its quarterly earnings results on Thursday, August 2nd. The medical instruments supplier reported ($0.03) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.13) by $0.10. Insulet had a negative return on equity of 11.91% and a negative net margin of 3.47%. The company had revenue of $124.26 million during the quarter, compared to analysts’ expectations of $132.89 million. During the same quarter in the prior year, the business posted ($0.13) earnings per share. The company’s revenue for the quarter was up 13.2% compared to the same quarter last year. sell-side analysts predict that Insulet Co. will post -0.09 earnings per share for the current year.

A number of equities research analysts have recently weighed in on PODD shares. Zacks Investment Research downgraded Insulet from a “buy” rating to a “hold” rating in a report on Friday, August 17th. BidaskClub downgraded Insulet from a “buy” rating to a “hold” rating in a report on Wednesday, July 18th. Morgan Stanley boosted their price target on Insulet from $87.00 to $96.00 and gave the company an “equal weight” rating in a report on Friday, June 1st. Jefferies Financial Group reiterated a “buy” rating and issued a $97.00 price target on shares of Insulet in a report on Friday, August 3rd. Finally, Piper Jaffray Companies boosted their price target on Insulet to $106.00 and gave the company an “overweight” rating in a report on Monday, June 4th. Four analysts have rated the stock with a hold rating, thirteen have issued a buy rating and three have assigned a strong buy rating to the stock. The company has an average rating of “Buy” and an average price target of $95.24.

Several large investors have recently added to or reduced their stakes in PODD. SG Americas Securities LLC grew its stake in shares of Insulet by 63.6% in the first quarter. SG Americas Securities LLC now owns 3,837 shares of the medical instruments supplier’s stock worth $333,000 after purchasing an additional 1,492 shares in the last quarter. Swiss National Bank lifted its holdings in shares of Insulet by 2.2% in the first quarter. Swiss National Bank now owns 101,100 shares of the medical instruments supplier’s stock valued at $8,763,000 after buying an additional 2,200 shares during the period. State of Wisconsin Investment Board acquired a new stake in shares of Insulet in the first quarter valued at $3,467,000. Schwab Charles Investment Management Inc. lifted its holdings in shares of Insulet by 11.1% in the first quarter. Schwab Charles Investment Management Inc. now owns 307,737 shares of the medical instruments supplier’s stock valued at $26,675,000 after buying an additional 30,807 shares during the period. Finally, Eagle Asset Management Inc. acquired a new stake in shares of Insulet in the first quarter valued at $47,002,000.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod Insulin Management System (Omnipod System), which consists of an easy-to-use continuous insulin delivery system; and Personal Diabetes Manager, a handheld wireless device.

Featured Story: Return on Investment (ROI) Defined, Explained

Insider Buying and Selling by Quarter for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.